Merck has other promising candidates in its late-stage pipeline, such as MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis and ...

For now though, any threat from Merck's drug is speculative ... AstraZeneca meanwhile is also working on an oral PCSK9 inhibitor that it acquired from Dogma Therapeutics last year and is in ...

AZ is now planning to move ahead with a phase 2 programme for its drug, although there’s no doubt it is playing catch-up in the oral PCSK9 inhibitor category with MSD – known as Merck & Co in ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

Merck & Co., Inc. (NYSE:MRK) is developing an oral PCSK9 inhibitor, enlicitide, which is positioned as the most potent oral LDL-lowering medicine. This medicine aims to become a cost-effective ...

The decision to opt for HS-10535 over another candidate, HS-10501, is believed to be due to better combinability potential, particularly with Merck’s oral PCSK9, which could enhance the ...

Merck & Co., Inc. (NYSE:MRK) is advancing the development of enlicitide, an oral PCSK9 inhibitor positioned as the most potent oral LDL-lowering medicine. This drug is designed to offer a cost ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...